Sanctuary Advisors LLC Takes $165,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Sanctuary Advisors LLC bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,270 shares of the company’s stock, valued at approximately $165,000. Sanctuary Advisors LLC owned approximately 0.07% of Aquestive Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at about $27,000. SG Americas Securities LLC purchased a new stake in Aquestive Therapeutics in the first quarter worth about $54,000. Lazard Asset Management LLC boosted its position in Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $76,000. Finally, Financial Advocates Investment Management raised its position in shares of Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AQST shares. HC Wainwright lifted their price target on Aquestive Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, September 30th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $12.00 price target (up from $10.00) on shares of Aquestive Therapeutics in a research note on Monday, September 30th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average target price of $8.67.

Aquestive Therapeutics Stock Up 2.2 %

Shares of NASDAQ AQST opened at $5.03 on Monday. The company has a 50 day moving average of $4.63 and a 200 day moving average of $3.71. Aquestive Therapeutics, Inc. has a twelve month low of $1.36 and a twelve month high of $6.23. The firm has a market cap of $457.93 million, a P/E ratio of -11.98 and a beta of 2.85.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.